With a yearly budget of nearly $48 billion, the NIH is the world’s largest public funder of biomedical research. The agency's ...

The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...